Browse

Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome

Cited 0 time in Web of Science Cited 0 time in Scopus
Authors
Kim, Yun-Kyung; Pai, Hyunjoo; Lee, Hoan-Jong; Park, Su-Eun; Choi, Eun-Hwa; Kim, Jungmin; Kim, Je-Hak; Kim, Eui-Chong
Issue Date
2002-04-18
Publisher
American Society for Microbiology
Citation
Antimicrob Agents Chemother. 2002 May;46(5):1481-91.
Keywords
AdolescentAnti-Bacterial Agents/therapeutic useBacteremia/drug therapy/*epidemiology/*microbiology/physiopathologyChildChild, PreschoolDrug Resistance, Bacterial/geneticsElectrophoresis, Gel, Pulsed-FieldEscherichia coli/*enzymologyEscherichia coli Infections/drugtherapy/epidemiology/microbiology/physiopathologyFemaleHumansInfantInfant, NewbornKlebsiella Infections/drugtherapy/epidemiology/microbiology/physiopathologyKlebsiella pneumoniae/*enzymologyMalePrevalenceRetrospective StudiesRisk FactorsTreatment Outcomebeta-Lactamases/genetics/*metabolism
Abstract
To determine the epidemiologic features and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae isolates, cases of bacteremia caused by these organisms in children were analyzed retrospectively. Among the 157 blood isolates recovered from 1993 to 1998 at the Seoul National University Children's Hospital, the prevalence of ESBL production was 17.9% among the E. coli isolates and 52.9% among the K. pneumoniae isolates. The commonest ESBLs were SHV-2a and TEM-52. A novel ESBL, TEM-88, was identified. Pulsed-field gel electrophoresis analysis of the ESBL-producing organisms showed extensive diversity in clonality. The medical records of 142 episodes were reviewed. The risk factors for bloodstream infection with ESBL-producing organisms were prior hospitalization, prior use of oxyimino-cephalosporins, and admission to an intensive care unit within the previous month. There was no difference in clinical severity between patients infected with ESBL-producing strains (the ESBL group) and those infected with ESBL-nonproducing strains (the non-ESBL group) at the time of presentation. However, the overall fatality rate for the ESBL group was significantly higher than that for the non-ESBL group: 12 of 45 (26.7%) versus 5 of 87 (5.7%) (P = 0.001). In a subset analysis of patients treated with extended-spectrum cephalosporins with or without an aminoglycoside, favorable response rates were significantly higher in the non-ESBL group at the 3rd day (6 of 17 versus 33 of 51; P = 0.035), the 5th day (6 of 17 versus 36 of 50; P < 0.05), and the end of therapy (9 of 17 versus 47 of 50; P < 0.001). In conclusion, the ESBL production of the infecting organisms has a significant impact on the clinical course and survival of pediatric patients with bacteremia caused by E. coli and K. pneumoniae.
ISSN
0066-4804 (Print)
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11959586

http://hdl.handle.net/10371/11604
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Pediatrics (소아과학전공)Journal Papers (저널논문_소아과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse